Skip to main content
Clinical Trials/CTRI/2020/07/026555
CTRI/2020/07/026555
Completed
未知

Active Safety surveillance study in pediatric patients of Childhood onset Nephrotic Syndrome on Rituximab therapy

INSTITUTIONAL RESEARCH FUND0 sites30 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: N041- Nephrotic syndrome with focal andsegmental glomerular lesions
Sponsor
INSTITUTIONAL RESEARCH FUND
Enrollment
30
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Observational

Investigators

Sponsor
INSTITUTIONAL RESEARCH FUND

Eligibility Criteria

Inclusion Criteria

  • 1\.Diagnosed cases of childhood onset nephrotic syndrome \<\=18 years of age, of any gender, who have either received at least one dose of RTX in the last 3 months or shall receive rituximab in our hospital.
  • 2\.Subjects willing to give written informed consent and comply with study related instructions

Exclusion Criteria

  • 1\.Subjects unwilling to give written informed consent and comply with study related instructions.
  • 2\.Subjects on rituximab therapy for any non\-renal indications.
  • 3\.Subjects who have received the last dose of RTX more than 3 months back.

Outcomes

Primary Outcomes

Not specified

Similar Trials